
Theophylline Anhydrous is a high-purity methylxanthine bronchodilator engineered for the global pharmaceutical manufacturing sector with CAS number 58-55-9. Characterized by its stable, water-free crystalline matrix, this premium active compound serves as a critical component in synthesizing clinical-strength anti-asthmatic oral therapies, sustained-release tablets, and targeted respiratory healthcare solutions.
Exceptional digestibility and rapid absorption provide a major competitive advantage in the formulation of therapeutic treatments. This active pharmaceutical ingredient works by providing the essential structural mechanisms—specifically inhibiting phosphodiesterase enzymes and suppressing airway response to stimuli—needed for effective airway passage modulation. It helps manufacturers achieve potent therapeutic profiles in anti-asthmatic medical products without sacrificing formula stability. For instance, Theophylline Anhydrous is frequently used as a primary ingredient in clinical-strength chronic obstructive pulmonary disease (COPD) therapies. Consequently, it improves the clinical efficacy of chronic bronchospasm treatments. As a result, Zyntex ensures low heavy metal content and strict microbiological control for our supply, ensuring maximum safety during your manufacturing cycle.
Moreover, Zyntex supplies specialized micronized grades for the clinical medicine industry. This compound acts as a critical nutritional fortifier, helping to enhance the defense mechanisms of patients undergoing respiratory treatment protocols. It pushes the boundaries of medical science by offering a heat-stable active source that does not affect the final solution’s viscosity. At the same time, it serves as a crucial biomaterial in the synthesis of specialized prolonged-release matrices and pulmonary health tablets. In short, our product serves as a dependable “structural matrix.” It supports both the vitality of the human body and the precision of biomedical engineering.
Recently, scientific interest in its application for eco-friendly biodegradable therapeutic coatings and target-release granules has grown. It provides a natural and potent alternative to synthetic options in specific target delivery applications. Because of this, Zyntex offers refined chemical grades designed to meet the rigorous specifications of modern sustainable pharmaceutical research. Ultimately, choosing Zyntex secures a reliable and transparent chemical supply chain. We balance core chemistry expertise with rigorous quality monitoring. To conclude, our commitment ensures your Theophylline Anhydrous manufacturing processes achieve the highest levels of clinical performance and purity.
This high-purity bioavailable bronchodilator is essential in these four primary sectors:
Primary source for capsule and sustained-release oral medications. Thus, it provides essential support for long-term airway disease management.
Key chemical active for prolonged systemic delivery profiles. Undoubtedly, it is vital for maintaining uniform therapeutic plasma levels over 24 hours.
Used for target methylxanthine interactions and phosphodiesterase inhibition protocols. Consequently, it is vital for high-performance medical science.
Acts as a reliable therapeutic active in critical prescription formulations. Specifically, it supports rapid patient lung function recovery and safety management.
| Parameter | Standard Value |
|---|---|
| Product Name | Theophylline Anhydrous (USP/EP Pharmaceutical Grade) |
| Assay / Purity | 99.0% – 101.0% (Dried Basis) |
| Appearance | White, crystalline powder |
| CAS Number | 58-55-9 |
📝 Safety & Handling: Generally recognized as a potent bronchodilator agent. Therefore, store in a cool, dry place away from direct sunlight in an airtight container. Protect from moisture and ambient humidity to maintain complete anhydrous pharmaceutical potency. Use standard medical-grade PPE including dust masks, gloves, and lab protection during large-scale manufacturing handling. Always consult the Safety Data Sheet (SDS) for detailed storage and handling protocols.